Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Instinet Starts Sarepta Therapeutics (SRPT) at Buy, $84 PT
March 1, 2017 4:24 PM ESTInstinet initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $84.00.
Analyst Christopher Marai commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant... More
Sarepta Therapeutics (SRPT) Sees Strong Red-to-Green Reversal
March 1, 2017 11:17 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reverses large after-hours losses and goes positive as CMS update adds pass-thru drug code C9484 or Eteplirsen. LINK
Shares are up 1.4%.
... More
